Intravitreal Brolucizumab for Chronic Central Serous Chorioretinopathy without Choroidal Neovascular Membrane - a Pilot Study.

Srishti Raksheeth RamamurthyUmesh Chandra BeheraRitesh NarulaSriniVas R SaddaRaja Narayanan

Published in: Seminars in ophthalmology (2024)

Intravitreal brolucizumab is effective in the rapid reduction of persistent macular fluid in chronic CSCR without CNVM. Long-term follow-up data are required to study recurrence and adverse effect profile.

Keyphrases

age related macular degeneration
vascular endothelial growth factor
diabetic retinopathy
optical coherence tomography
high grade
electronic health record
emergency department
adverse drug
data analysis
sensitive detection